The role of sentinel node biopsy in patients with cutaneous melanoma.
The role of sentinel lymph node biopsy (SLNB) as a prognostic indicator in melanoma patients has been controversial in the fields of surgical oncology and dermatology for decades. This minimally invasive surgical technique was introduced in 1990 for diagnosing melanoma lymphatic metastases and has been deemed the standard of surgical care of cutaneous malignant melanoma by the World Health Organization and the Sunbelt Melanoma Clinical Trial. Its usefulness as a prognostic indicator of metastases led to expanded applications for breast, colon, gastric, esophageal, head and neck, thyroid, and lung cancers. This article first provides an overview of cutaneous melanoma and staging methods and treatment modalities. A brief study of the lymphatic system and the SLNB procedure are reviewed, followed by a discussion of its usefulness in patients who have melanoma, including risks and benefits. This article also discusses nursing considerations for patients undergoing the procedure, and patient education tips. Lastly, future indications for SLNB and new prognostic indicators for melanoma are discussed.
Aldredge
Lakshi M
LM
Dermatology Service, Portland VA Medical Center, Portland, OR 97207, USA. lakshi.aldredge@va.gov
D006801:Humans; D008545:Melanoma / Q000473:pathology*; D009367:Neoplasm Staging; D010353:Patient Education as Topic; D011379:Prognosis; D021701:Sentinel Lymph Node Biopsy / Q000009:adverse effects / Q000379:methods / Q000451:nursing*; D012878:Skin Neoplasms / Q000473:pathology*